Age, Biography and Wiki
David J. Galton was born on 2 May, 1937, is a British physician and researcher (born 1937). Discover David J. Galton's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 86 years old?
| Popular As |
N/A |
| Occupation |
N/A |
| Age |
86 years old |
| Zodiac Sign |
Taurus |
| Born |
2 May 1937 |
| Birthday |
2 May |
| Birthplace |
N/A |
| Nationality |
|
We recommend you to check the complete list of Famous People born on 2 May.
He is a member of famous physician with the age 86 years old group.
David J. Galton Height, Weight & Measurements
At 86 years old, David J. Galton height not available right now. We will update David J. Galton's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status |
| Height |
Not Available |
| Weight |
Not Available |
| Body Measurements |
Not Available |
| Eye Color |
Not Available |
| Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
| Family |
| Parents |
Not Available |
| Wife |
Not Available |
| Sibling |
Not Available |
| Children |
Not Available |
David J. Galton Net Worth
His net worth has been growing significantly in 2023-2024. So, how much is David J. Galton worth at the age of 86 years old? David J. Galton’s income source is mostly from being a successful physician. He is from . We have estimated David J. Galton's net worth, money, salary, income, and assets.
| Net Worth in 2024 |
$1 Million - $5 Million |
| Salary in 2024 |
Under Review |
| Net Worth in 2023 |
Pending |
| Salary in 2023 |
Under Review |
| House |
Not Available |
| Cars |
Not Available |
| Source of Income |
physician |
David J. Galton Social Network
| Instagram |
|
| Linkedin |
|
| Twitter |
|
| Facebook |
|
| Wikipedia |
|
| Imdb |
|
Timeline
David Jeremy Galton (born 2 May 1937) is a British physician and researcher in molecular genetics and metabolic disease, primarily the hyperlipidemias and diabetes mellitus.
He is an authority figure in his field.
David Galton was educated at Highgate School London and graduated from University College London in 1957 with a BSc (first class honours) and MB.BS (with honours in medicine) in 1960.
After house-staff training he went to the National Institutes of Health, Bethesda Maryland, USA to study with Robert Scow and Martin Rodbell.
On returning to the UK he obtained a Fellowship at the Hammersmith Hospital to work with Russell Fraser and later elected to the consultant staff at St Bartholomew's Hospital London.
He was then elected to a Professorship, Department of Medicine, London University and is now an Emeritus Professor at London University.
Galton was elected Chairman of Clinical Science from 1978 to 1980.
He served on the scientific grants committee of Diabetes UK from 1984 to 1987 and again from 1989 to 1991.
He was elected secretary of the European Atherosclerosis Society from 1988 to 1993 and Chairman of HEART UK from 1999 to 2001.
He has been a Consultant Physician to St. Bartholomew's and Moorfield's Eye Hospitals.
He is currently serving as the librarian of the Galton Institute (formerly the British Eugenics Society) having previously served as vice-president.
He is no relation of Francis Galton.
His laboratory's main contributions have been to reveal defects of metabolic regulatory elements in common metabolic disease (mainly diabetes mellitus, the lipemias and atherosclerosis) at both phenotype and genotype levels:
His group identified the earliest loss of an allosteric regulation of a rate-determining enzyme, phosphofructokinase by citrate in minimal deviation tumours, lipomata.
Many more such defects have subsequently come to light particularly to deregulate pathways in early neoplasia.
Abnormalities in the covalent modification of peptide regulators were found to have effects on enzyme activity.
Thus one extra sialyl residue on apolipoprotein C3 impairs its action on lipoprotein lipase.
This can affect expression of the resulting phenotype of hypertriglyceridemia.
His laboratory was one of the first to use single nucleotide polymorphisms (SNPs) to reveal susceptibility genes that predispose individuals to develop metabolic disorders, such as hypertriglyceridemia and atherosclerosis.
This led eventually to the development of Genome Wide Association Studies (GWAS) where more than 1400 susceptibility loci have now been identified using SNPs and some have led to useful therapeutic agents such as volanesorsen
